Pharma News

the Chinese government approved a blueprint called “Healthy China 2030”, pledging to build a healthy China in the next 15 years. By 2030, the size of the healthcare market is expected to reach $2.3 trillion. This initiative is in line with China’s determination to deepen the supply-side structural reforms in 2017 by substantially driving down overcapacity, and increasing efficient supply which call for stricter standards in healthcare industry. The next 15 years will see a surge of investment and changes in the industry.

A question from the Parliament " regarding the influence of vaccine-makers on the immunisation plan" raised the issue of funding the Indian Academy of Pediatrics (IPA), the body representing more than 23,000 pediatricians in India. A look at its finances shows how much depends on the IPA on the financing of the pharmaceutical industry, especially the vaccine manufacturers.

The draft National Strategic Plan for the Eradication of Tuberculosis (2017-2025), which will be implemented shortly, offers benefits that include Rs2,000 for patients visiting private sector physicians. The Center is considering incentives for private doctors treating TB patients, as well as financial benefits and free medicines for those visiting them as part of its "aggressive" strategy to eliminate the disease.

[adsense:336x280:8701650588]

In order to make the new HIV and hepatitis B and C drugs available to patients at the earliest, the government has decided to abandon some of the regulatory processes to accelerate approvals.

US President Donald Trump demanded that Republican MPs vote Friday on a bill to repeal and replace the Affordable Care Act, also known as Obamacare.

The government said it was working on measures to reduce India's dependence on large-scale imports of active pharmaceutical ingredients (APIs), as members of Rajya Sabha expressed concern about question. Responding to zero-hour concerns, Trade Minister Nirmala Sitharaman said the huge imports of pharmaceutical raw materials were a matter of serious concern.

A high-level committee recommended a new institutional framework for homeopathy and Ayurveda in India, continuing its efforts to rationalize the country's medical system. The Committee stated that the statutory bodies governing the education system have failed to attract qualified and qualified people based on merit due to lack of transparency.

Prices for all essential medicines are likely to increase by almost 2% from 1 April. The National Pharmaceutical Pricing Authority (NPPA) has asked companies to submit the documents required to benefit from the annual price increase based on the wholesale price index. Under the Drugs Price Control Order, the regulator revises prices of all essential medicines annually based on the changes in WPI.

Achillion Pharmaceuticals, Inc announced that the U.S. Patent and Trademark Office (USPTO) has issued the first U.S. Patent to Achillion resulting from its complement factor D research program. U.S. Patent No. 9,598,446 has been granted with claims to compositions of matter for compounds that inhibit complement factor D activity, a key mediator in the complement alternative pathway (AP).

Using genetic testing to help personalize doses of warfarin therapy given to patients undergoing elective orthopedic surgery appears to lower the risk of combined adverse events compared with clinically guided dosing, according to research presented at the American College of Cardiology’s 66th Annual Scientific Session. Researchers said these findings could have implications for a broad population of patients starting warfarin therapy.